CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 21-283/S011

Chemistry Review(s)

CHEMIST'S REVIEW	1.ORGANIZATION HFD-110	2. NDA Number 21-283
3. Name and Address of Applicant (City & State) Novartis Pharmaceuticals Corp. East Hanover, New Jersey		4. Supplemental New Drug Application: Number(s) Date(s) S-011 12/17/03
5. Drug Name Diovan Tablets	6. Nonproprietary Name valsartan	8. Amendments & S/A (BC) 4/29/04
7. Supplement provides for Diovan tablets to be used in the treatment of post-myocardial infarction patients with the use of a newly formulated ovaloid 40 mg tablet.		
9. Pharmacological Category Control of hypertensive episodes in patients (phenochromocytoma)	10. How Dispensed (X)- Rx ( )-OTC	11. Related IND(s)/ NDA(s
12. Dosage Form: tablets	13. Potency(ies) 40mg, 80 mg, 160 mg and 320 mg	
14. Chemical Name: DESCRIPTION Diovan® (valsartan) is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT1 receptor subtype. Valsartan is chemically described as N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl) [1 biphenyl]-4-yl]methyl]-L-valine. Its empirical formula is $C_{24}H_{29}N_5O_3$, its molecular weight is 435.5, and its structural formula is 		15. Records/Reports Current

16. Comments: ***Summary of Information*** **(Submission Purpose)**: Novartis is currently seeking approval for a redesigned Diovan 40mg film-coated tablet for use in the treatment of post-myocardial infarction (post-MI). The post-MI indication requires the starting dose of 20mg of valsartan. For this reason, Novartis has redesigned the original round unscored Diovan 40mg film-coated tablet to be an ovaloid scored divisible tablet. There is intent to replace the round 40 mg tablet. No changes are proposed to any of the other tablet strengths. The supporting data indicate that there is strong correspondence for comparative testing results between the currently approved round tablet and the proposed ovaloid scored tablet with respect to all the tests that were conducted between tablets and the halves after breakage (e.g., dissolution, content uniformity, mass etc.). Adequate supporting drug product data (QC release data on the one pre-validation batch) is provided and considered to be adequate since it is expected to have an impact on stability and additional supporting stability studies is expected to be provided in the next several weeks to confirm this "no effect" expectation.

17. Conclusions and Recommendations: Recommend an approval letter from the standpoint of CMC review.

18.REVIEWER FILE NAME: S-011 W(6-28-04)

Name	Signature	Date Completed
Stuart Zimmerman		6/28/04 (rev. 7/9/04)

21 Page(s) Withheld

X § 552(b)(4) Trade Secret / Confidential

___ § 552(b)(5) Deliberative Process

___ § 552(b)(4) Draft Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Stuart Zimmerman
7/15/04 10:51:12 AM
CHEMIST

Kasturi Srinivasachar
7/16/04 10:08:31 AM
CHEMIST

NDA 21-283/S-011

At the filing meeting on January 29, 2004, it was decided that Establishment Inspections would not be needed for this efficacy supplement.

Methods Validation

Dr. Zimmerman stated that Methods Validation is not applicable to this efficacy supplement.